BET in hematologic tumors: Immunity, pathogenesis, clinical trials and drug combinations

Tao Ma; Yan Chen; Zhi-Gang Yi; Yan-Hong Li; Jun Bai; Li-Juan Li; Lian-Sheng Zhang

doi:10.1016/j.gendis.2022.03.004

您当前的位置：

首页 >

文章列表页 >

BET in hematologic tumors: Immunity, pathogenesis, clinical trials and drug combinations

Review article | 更新时间：2024-02-04

- BET in hematologic tumors: Immunity, pathogenesis, clinical trials and drug combinations
- Genes & Diseases Vol. 1, Issue 6, Pages: 2306-2319(2023)
- 作者机构：
  
  1. Department of Hematology, The Affiliated Hospital of Southwest Medical University,Sichuan,Luzhou,China,646000
  2. Department of Hematology, Lanzhou University Second Hospital,Gansu,Lanzhou,China,730000
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2022.03.004
  CLC：
- Published：2023，
  
  Published Online：1 November 2023，
扫描看全文
Tao Ma, Yan Chen, Zhi-Gang Yi, et al. BET in hematologic tumors: Immunity, pathogenesis, clinical trials and drug combinations. [J]. Genes & Diseases 1(6):2306-2319(2023)
DOI：

Tao Ma, Yan Chen, Zhi-Gang Yi, et al. BET in hematologic tumors: Immunity, pathogenesis, clinical trials and drug combinations. [J]. Genes & Diseases 1(6):2306-2319(2023) DOI： 10.1016/j.gendis.2022.03.004.

摘要

Abstract

The bromodomain and extra-terminal (BET) proteins act as “readers” for lysine acetylation and facilitate the recruitment of transcriptional elongation complexes. BET protein is associated with transcriptional elongation of genes such as

c-MYC

and

BCL-2

and is involved in the regulation of cell cycle and apoptosis. Meanwhile

BET inhibitors (BETi) have regulatory effects on immune checkpoints

immune cells

and cytokine expression. The role of BET proteins and BETi in a variety of tumors has been studied. This paper reviews the recent research progress of BET and BETi in hematologic tumors (mainly leukemia

lymphoma and multiple myeloma) from cellular level studies

animal studies

clinical trials

drug combination

etc. BETi has a promising future in hematologic tumors

and future research directions may focus on the combination with other drugs to improve the efficacy.

关键词

Keywords

BETBRD4Clinical trialsHematologic tumorsImmunityMYC

references

1 C. Dhalluin, J.E. Carlson, L. Zeng, et al.Structure and ligand of a histone acetyltransferase bromodomain Nature, 399 (6735) (1999), pp. 491-496

2 P. Filippakopoulos, S. KnappTargeting bromodomains: epigenetic readers of lysine acetylation Nat Rev Drug Discov, 13 (5) (2014), pp. 337-356

3 J. Shi, C.R. VakocThe mechanisms behind the therapeutic activity of BET bromodomain inhibition Mol Cell, 54 (5) (2014), pp. 728-736

4 N. Wang, R. Wu, D. Tang, R. KangThe BET family in immunity and disease Signal Transduct Target Ther, 6 (1) (2021), p. 23

5 Y. Duan, Y. Guan, W. Qin, X. Zhai, B. Yu, H. LiuTargeting Brd4 for cancer therapy: inhibitors and degraders Medchemcomm, 9 (11) (2018), pp. 1779-1802

6 B.N. Devaiah, C. Case-Borden, A. Gegonne, et al.BRD4 is a histone acetyltransferase that evicts nucleosomes from chromatin Nat Struct Mol Biol, 23 (6) (2016), pp. 540-548

7 B. Donati, E. Lorenzini, A. CiarrocchiBRD4 and cancer: going beyond transcriptional regulation Mol Cancer, 17 (1) (2018), p. 164

8 B.N. Devaiah, J. Mu, B. Akman, et al.MYC protein stability is negatively regulated by BRD4 Proc Natl Acad Sci USA, 117 (24) (2020), pp. 13457-13467

9 Z.Y. Qin, T. Wang, S. Su, et al.BRD4 promotes gastric cancer progression and metastasis through acetylation-dependent stabilization of snail Cancer Res, 79 (19) (2019), pp. 4869-4881

10 S.Y. Wu, C.F. Lee, H.T. Lai, et al.Opposing functions of BRD4 isoforms in breast cancer Mol Cell, 78 (6) (2020), pp. 1114-1132 e10

11 A.P. Szczepanski, Z. Zhao, T. Sosnowski, Y.A. Goo, E.T. Bartom, L. WangASXL3 bridges BRD4 to BAP1 complex and governs enhancer activity in small cell lung cancer Genome Med, 12 (1) (2020), p. 63

12 F. Bray, J. Ferlay, I. Soerjomataram, R.L. Siegel, L.A. Torre, A. JemalGlobal cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA A Cancer J Clin, 68 (6) (2018), pp. 394-424

13 J. Nordlund, A.C. SyvänenEpigenetics in pediatric acute lymphoblastic leukemia Semin Cancer Biol, 51 (2018), pp. 129-138

14 K.K. Jovanović, C. Roche-Lestienne, I.M. Ghobrial, T. Facon, B. Quesnel, S. ManierTargeting MYC in multiple myeloma Leukemia, 32 (6) (2018), pp. 1295-1306

15 P.A. Jones, H. Ohtani, A. Chakravarthy, D.D. De CarvalhoEpigenetic therapy in immune-oncology Nat Rev Cancer, 19 (3) (2019), pp. 151-161

16 A. Nebbioso, F.P. Tambaro, C. Dell’Aversana, L. AltucciCancer epigenetics: moving forward PLoS Genet, 14 (6) (2018), p. e1007362

17 M.A. Dawson, T. KouzaridesCancer epigenetics: from mechanism to therapy Cell, 150 (1) (2012), pp. 12-27

18 E. Verdin, M. Ott50 years of protein acetylation: from gene regulation to epigenetics, metabolism and beyond Nat Rev Mol Cell Biol, 16 (4) (2015), pp. 258-264

19 R. Marmorstein, M.M. ZhouWriters and readers of histone acetylation: structure, mechanism, and inhibition Cold Spring Harbor Perspect Biol, 6 (7) (2014), p. a018762

20 C.R. Paradise, M.L. Galvan, E. Kubrova, et al.The epigenetic reader Brd4 is required for osteoblast differentiation J Cell Physiol, 235 (6) (2020), pp. 5293-5304

21 M. Gonzales-Cope, S. Sidoli, N.V. Bhanu, K.J. Won, B.A. GarciaHistone H4 acetylation and the epigenetic reader Brd4 are critical regulators of pluripotency in embryonic stem cells BMC Genom, 17 (2016), p. 95

22 P. StrzyzChromatin: BRD4 kicks out nucleosomes with its HAT Nat Rev Mol Cell Biol, 17 (7) (2016), pp. 396-397

23 J. Lovén, H.A. Hoke, C.Y. Lin, et al.Selective inhibition of tumor oncogenes by disruption of super-enhancers Cell, 153 (2) (2013), pp. 320-334

24 M. Ceribelli, P.N. Kelly, A.L. Shaffer, et al.Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors Proc Natl Acad Sci USA, 111 (31) (2014), pp. 11365-11370

25 J.E. Roderick, J. Tesell, L.D. Shultz, et al.c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells Blood, 123 (7) (2014), pp. 1040-1050

26 A. Sabò, B. AmatiBRD4 and MYC—clarifying regulatory specificity Science, 360 (6390) (2018), pp. 713-714

27 G. Deng, F. Zeng, J. Su, et al.BET inhibitor suppresses melanoma progression via the noncanonical NF-κB/SPP1 pathway Theranostics, 10 (25) (2020), pp. 11428-11443

28 G. Ambrosini, C. Do, B. Tycko, et al.Inhibition of NF-κB-dependent signaling enhances sensitivity and overcomes resistance to BET inhibition in uveal melanoma Cancer Res, 79 (9) (2019), pp. 2415-2425

29 T. Wu, G. Wang, W. Chen, et al.Co-inhibition of BET proteins and NF-κB as a potential therapy for colorectal cancer through synergistic inhibiting MYC and FOXM1 expressions Cell Death Dis, 9 (3) (2018), p. 315

30 X. Wu, J. Qi, J.E. Bradner, G. Xiao, L.F. ChenBromodomain and extraterminal (BET) protein inhibition suppresses human T cell leukemia virus 1 (HTLV-1) Tax protein-mediated tumorigenesis by inhibiting nuclear factor κB (NF-κB) signaling J Biol Chem, 288 (50) (2013), pp. 36094-36105

31 E.E. Stratikopoulos, M. Dendy, M. Szabolcs, et al.Kinase and BET inhibitors together clamp inhibition of PI3K signaling and overcome resistance to therapy Cancer Cell, 27 (6) (2015), pp. 837-851

32 S. Shigeta, G.Y.L. Lui, R. Shaw, et al.Targeting BET proteins BRD2 and BRD3 in combination with PI3K-AKT inhibition as a therapeutic strategy for ovarian clear cell carcinoma Mol Cancer Therapeut, 20 (4) (2021), pp. 691-703

33 S.N. Loganathan, N. Tang, A.E. Holler, N. Wang, J. WangTargeting the IGF1R/PI3K/AKT pathway sensitizes ewing sarcoma to BET bromodomain inhibitors Mol Cancer Therapeut, 18 (5) (2019), pp. 929-936

34 E.E. Stratikopoulos, R.E. ParsonsMolecular pathways: targeting the PI3K pathway in cancer-BET inhibitors to the rescue Clin Cancer Res, 22 (11) (2016), pp. 2605-2610

35 T. Bagratuni, N. Mavrianou, N.G. Gavalas, et al.JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer Eur J Cancer, 126 (2020), pp. 125-135

36 Y. Ma, L. Wang, L.R. Neitzel, et al.The MAPK pathway regulates intrinsic resistance to BET inhibitors in colorectal cancer Clin Cancer Res, 23 (8) (2017), pp. 2027-2037

37 T. Shorstova, W.D. Foulkes, M. WitcherAchieving clinical success with BET inhibitors as anti-cancer agents Br J Cancer, 124 (9) (2021), pp. 1478-1490

38 T. Shorstova, M. Marques, J. Su, et al.SWI/SNF-compromised cancers are susceptible to bromodomain inhibitors Cancer Res, 79 (10) (2019), pp. 2761-2774

39 T.C. Yeh, G. O'Connor, P. Petteruti, et al.Identification of CCR2 and CD180 as robust pharmacodynamic tumor and blood biomarkers for clinical use with BRD4/BET inhibitors Clin Cancer Res, 23 (4) (2017), pp. 1025-1035

40 X. Lin, X. Huang, T. Uziel, et al.HEXIM1 as a robust pharmacodynamic marker for monitoring target engagement of BET family bromodomain inhibitors in tumors and surrogate tissues Mol Cancer Therapeut, 16 (2) (2017), pp. 388-396

41 P. Filippakopoulos, J. Qi, S. Picaud, et al.Selective inhibition of BET bromodomains Nature, 468 (7327) (2010), pp. 1067-1073

42 A. Chaidos, V. Caputo, K. Gouvedenou, et al.Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762 Blood, 123 (5) (2014), pp. 697-705

43 G.E. Winter, D.L. Buckley, J. Paulk, et al.DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation Science, 348 (6241) (2015), pp. 1376-1381

44 J. Lu, Y. Qian, M. Altieri, et al.Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4 Chem Biol, 22 (6) (2015), pp. 755-763

45 F. Spriano, A. Stathis, F. BertoniTargeting BET bromodomain proteins in cancer: the example of lymphomas Pharmacol Ther, 215 (2020), p. 107631

46 H. Zhu, F. Bengsch, N. Svoronos, et al.BET bromodomain inhibition promotes anti-tumor immunity by suppressing PD-L1 expression Cell Rep, 16 (11) (2016), pp. 2829-2837

47 S.C. Casey, L. Tong, Y. Li, et al.MYC regulates the antitumor immune response through CD47 and PD-L1 Science, 352 (6282) (2016), pp. 227-231

48 S.J. Hogg, S.J. Vervoort, S. Deswal, et al.BET-bromodomain inhibitors engage the host immune system and regulate expression of the immune checkpoint ligand PD-L1 Cell Rep, 18 (9) (2017), pp. 2162-2174

49 G.P. Andrieu, J.S. Shafran, C.L. Smith, et al.BET protein targeting suppresses the PD-1/PD-L1 pathway in triple-negative breast cancer and elicits anti-tumor immune response Cancer Lett, 465 (2019), pp. 45-58

50 K. Liu, Z. Zhou, H. Gao, et al.JQ1, a BET-bromodomain inhibitor, inhibits human cancer growth and suppresses PD-L1 expression Cell Biol Int, 43 (6) (2019), pp. 642-650

51 N. Nikbakht, M. Tiago, D.A. Erkes, I. Chervoneva, A.E. AplinBET inhibition modifies melanoma infiltrating T cells and enhances response to PD-L1 blockade J Invest Dermatol, 139 (7) (2019), pp. 1612-1615

52 X. Lai, A. Stiff, M. Duggan, R. Wesolowski, W.E. Carson 3rd, A. FriedmanModeling combination therapy for breast cancer with BET and immune checkpoint inhibitors Proc Natl Acad Sci USA, 115 (21) (2018), pp. 5534-5539

53 L.C. Wellinger, S.J. Hogg, D.M. Newman, et al.BET inhibition enhances TNF-mediated antitumor immunity Cancer Immunol Res, 10 (1) (2022), pp. 87-107

54 D.A. Erkes, C.O. Field, C. Capparelli, et al.The next-generation BET inhibitor, PLX51107, delays melanoma growth in a CD8-mediated manner Pigment Cell Melanoma Res, 32 (5) (2019), pp. 687-696

55 S.N. Copsel, C.O. Lightbourn, H. Barreras, et al.BET bromodomain inhibitors which permit treg function enable a combinatorial strategy to suppress GVHD in pre-clinical allogeneic HSCT Front Immunol, 9 (2019), p. 3104

56 J. Sánchez-Ventura, J. Amo-Aparicio, X. Navarro, C. PenasBET protein inhibition regulates cytokine production and promotes neuroprotection after spinal cord injury J Neuroinflammation, 16 (1) (2019), p. 124

57 S. Meng, L. Zhang, Y. Tang, et al.BET inhibitor JQ1 blocks inflammation and bone destruction J Dent Res, 93 (7) (2014), pp. 657-662

58 X. Hu, L.P. Schewitz-Bowers, P.J.P. Lait, et al.The bromodomain and extra-terminal protein inhibitor OTX015 suppresses T helper cell proliferation and differentiation Curr Mol Med, 18 (9) (2018), pp. 594-601

59 D.A. Mele, A. Salmeron, S. Ghosh, H.R. Huang, B.M. Bryant, J.M. LoraBET bromodomain inhibition suppresses TH17-mediated pathology J Exp Med, 210 (11) (2013), pp. 2181-2190

60 N. Remke, S. Bisht, S. Oberbeck, J. Nolting, P. BrossartSelective BET-bromodomain inhibition by JQ1 suppresses dendritic cell maturation and antigen-specific T-cell responses Cancer Immunol Immunother, 70 (1) (2021), pp. 107-121

61 Y. Sun, Y. Wang, T. Toubai, et al.BET bromodomain inhibition suppresses graft-versus-host disease after allogeneic bone marrow transplantation in mice Blood, 125 (17) (2015), pp. 2724-2728

62 R.J. Mills, S.J. Humphrey, P.R.J. Fortuna, et al.BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection Cell, 184 (8) (2021), pp. 2167-2182 e22

63 J. Zuber, J. Shi, E. Wang, et al.RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia Nature, 478 (7370) (2011), pp. 524-528

64 F. Basheer, B.J. HuntlyBET bromodomain inhibitors in leukemia Exp Hematol, 43 (8) (2015), pp. 718-731

65 M.A. Dawson, R.K. Prinjha, A. Dittmann, et al.Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia Nature, 478 (7370) (2011), pp. 529-533

66 M.A. Dawson, E.J. Gudgin, S.J. Horton, et al.Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia Leukemia, 28 (2) (2014), pp. 311-320

67 W. Fiskus, S. Sharma, J. Qi, et al.Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells Mol Cancer Therapeut, 13 (5) (2014), pp. 1142-1154

68 C.A.G. Booth, N. Barkas, W.H. Neo, et al.Ezh2 and Runx1 mutations collaborate to initiate lympho-myeloid leukemia in early thymic progenitors Cancer Cell, 33 (2) (2018), pp. 274-291 e8

69 W. Fiskus, S. Sharma, J. Qi, et al.BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD Mol Cancer Therapeut, 13 (10) (2014), pp. 2315-2327

70 L. Lee, Y. Hizukuri, P. Severson, et al.A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia Haematologica, 106 (4) (2021), pp. 1022-1033

71 H.J. Stewart, G.A. Horne, S. Bastow, T.J. ChevassutBRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1 Cancer Med, 2 (6) (2013), pp. 826-835

72 A.L. Latif, A. Newcombe, S. Li, et al.BRD4-mediated repression of p53 is a target for combination therapy in AML Nat Commun, 12 (1) (2021), p. 241

73 D.T. Saenz, W. Fiskus, T. Manshouri, et al.BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells Leukemia, 31 (3) (2017), pp. 678-687

74 C. Berthon, E. Raffoux, X. Thomas, et al.Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study Lancet Haematol, 3 (4) (2016), pp. e186-e195

75 G.J. Roboz, P. Desai, S. Lee, et al.A dose escalation study of RO6870810/TEN-10 in patients with acute myeloid leukemia and myelodysplastic syndrome Leuk Lymphoma, 62 (7) (2021), pp. 1740-1748

76 G. Borthakur, O. Odenike, I. Aldoss, et al.A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia Cancer, 127 (16) (2021), pp. 2943-2953

77 L. Zhang, T. Cai, X. Lin, et al.Selective inhibition of the second bromodomain of BET family proteins results in robust antitumor activity in preclinical models of acute myeloid leukemia Mol Cancer Therapeut, 20 (10) (2021), pp. 1809-1819

78 C.Y. Fong, O. Gilan, E.Y. Lam, et al.BET inhibitor resistance emerges from leukaemia stem cells Nature, 525 (7570) (2015), pp. 538-542

79 F.V. Pericole, M. Lazarini, L.B. de Paiva, et al.BRD4 inhibition enhances azacitidine efficacy in acute myeloid leukemia and myelodysplastic syndromes Front Oncol, 9 (2019), p. 16

80 J.A. Mertz, A.R. Conery, B.M. Bryant, et al.Targeting MYC dependence in cancer by inhibiting BET bromodomains Proc Natl Acad Sci USA, 108 (40) (2011), pp. 16669-16674

81 S. Wu, Y. Jiang, Y. Hong, et al.BRD4 PROTAC degrader ARV-825 inhibits T-cell acute lymphoblastic leukemia by targeting ‘Undruggable’ Myc-pathway genes Cancer Cell Int, 21 (1) (2021), p. 230

82 S. Peirs, V. Frismantas, F. Matthijssens, et al.Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia Leukemia, 31 (10) (2017), pp. 2037-2047

83 B. Zhou, J. Hu, F. Xu, et al.Discovery of a small-molecule degrader of bromodomain and extra-terminal (BET) proteins with picomolar cellular potencies and capable of achieving tumor regression J Med Chem, 61 (2) (2018), pp. 462-481

84 E. Kim, E. Ten Hacken, M. Sivina, et al.The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment Leukemia, 34 (6) (2020), pp. 1588-1598

85 W. Li, S.K. Gupta, W. Han, et al.Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors J Hematol Oncol, 12 (1) (2019), p. 73

86 P.A. Riedell, S.M. SmithDouble hit and double expressors in lymphoma: definition and treatment Cancer, 124 (24) (2018), pp. 4622-4632

87 M. Dickinson, J. Briones, A.F. Herrera, et al.Phase Ib study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma Blood Adv, 5 (22) (2021), pp. 4762-4770

88 G.I. Shapiro, P. LoRusso, A. Dowlati, et al.A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma Br J Cancer, 124 (4) (2021), pp. 744-753

89 S. Amorim, A. Stathis, M. Gleeson, et al.Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study Lancet Haematol, 3 (4) (2016), pp. e196-e204

90 W. Fiskus, C.P. Mill, D. Perera, et al.BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma Leukemia, 35 (9) (2021), pp. 2621-2634

91 C.C. Chen, C.C. Hsu, S.L. Chen, et al.RAS mediates BET inhibitor-endued repression of lymphoma migration and prognosticates a novel proteomics-based subgroup of DLBCL through its negative regulator IQGAP3 Cancers, 13 (19) (2021), p. 5024

92 B. Sun, B. Shah, W. Fiskus, et al.Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib Blood, 126 (13) (2015), pp. 1565-1574 Blood. 2015;126(13):1565–1574

93 B. Sun, W. Fiskus, Y. Qian, et al.BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells Leukemia, 32 (2) (2018), pp. 343-352

94 A. Moros, V. Rodríguez, I. Saborit-Villarroya, et al.Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma Leukemia, 28 (10) (2014), pp. 2049-2059

95 R. Kohnken, B. McNeil, J. Wen, et al.Preclinical targeting of microRNA-214 in cutaneous T-cell lymphoma J Invest Dermatol, 139 (9) (2019), pp. 1966-1974 e3

96 H. Kamijo, M. Sugaya, N. Takahashi, et al.BET bromodomain inhibitor JQ1 decreases CD30 and CCR4 expression and proliferation of cutaneous T-cell lymphoma cell lines Arch Dermatol Res, 309 (6) (2017), pp. 491-497

97 L. Zhao, J.P. Okhovat, E.K. Hong, Y.H. Kim, G.S. WoodPreclinical studies support combined inhibition of BET family proteins and histone deacetylases as epigenetic therapy for cutaneous T-cell lymphoma Neoplasia, 21 (1) (2019), pp. 82-92

98 S. Yumeen, F.N. Mirza, J.M. Lewis, et al.JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL Blood Adv, 4 (10) (2020), pp. 2213-2226

99 R. Schmitz, R.M. Young, M. Ceribelli, et al.Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics Nature, 490 (7418) (2012), pp. 116-120

100 K. Tomska, R. Kurilov, K.S. Lee, et al.Drug-based perturbation screen uncovers synergistic drug combinations in Burkitt lymphoma Sci Rep, 8 (1) (2018), p. 12046

101 M.G. Cortiguera, L. García-Gaipo, S.D. Wagner, J. León, A. Batlle-López, M.D. DelgadoSuppression of BCL6 function by HDAC inhibitor mediated acetylation and chromatin modification enhances BET inhibitor effects in B-cell lymphoma cells Sci Rep, 9 (1) (2019), p. 16495

102 S.J. Matissek, W. Han, M. Karbalivand, et al.Epigenetic targeting of Waldenström macroglobulinemia cells with BET inhibitors synergizes with BCL2 or histone deacetylase inhibition Epigenomics, 13 (2) (2021), pp. 129-144

103 R. Gopalakrishnan, H. Matta, B. Tolani, T. Triche Jr., P.M. ChaudharyImmunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors Oncogene, 35 (14) (2016), pp. 1797-1810

104 M. Boi, M. Todaro, V. Vurchio, et al.Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes Oncotarget, 7 (48) (2016), pp. 79637-79653

105 F. Zhan, B. Barlogie, V. Arzoumanian, et al.Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis Blood, 109 (4) (2007), pp. 1692-1700

106 M. Mattioli, L. Agnelli, S. Fabris, et al.Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma Oncogene, 24 (15) (2005), pp. 2461-2473

107 J.E. Delmore, G.C. Issa, M.E. Lemieux, et al.BET bromodomain inhibition as a therapeutic strategy to target c-Myc Cell, 146 (6) (2011), pp. 904-917

108 N. Imayoshi, M. Yoshioka, J. Chauhan, et al.CG13250, a novel bromodomain inhibitor, suppresses proliferation of multiple myeloma cells in an orthotopic mouse model Biochem Biophys Res Commun, 484 (2) (2017), pp. 262-268

109 N.H. Guo, J.F. Zheng, F.M. Zi, J. ChengI-BET151 suppresses osteoclast formation and inflammatory cytokines secretion by targetting BRD4 in multiple myeloma Biosci Rep, 39 (5) (2019), p. 1245 BSR20181245

110 J. Shi, S. Song, H. Han, et al.Potent activity of the bromodomain inhibitor OTX015 in multiple myeloma Mol Pharm, 15 (9) (2018), pp. 4139-4147

111 J. Gu, S. Song, H. Han, et al.The BET bromodomain inhibitor OTX015 synergizes with targeted agents in multiple myeloma Mol Pharm, 15 (11) (2018), pp. 5387-5396

112 X. Zhang, H.C. Lee, F. Shirazi, et al.Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma Leukemia, 32 (10) (2018), pp. 2224-2239

113 S.L. Lim, L. Xu, B.C. Han, P. Shyamsunder, W.J. Chng, H.P. KoefflerMultiple myeloma: combination therapy of BET proteolysis targeting chimeric molecule with CDK9 inhibitor PLoS One, 15 (6) (2020), Article e0232068

114 K. Ramasamy, A. Nooka, H. Quach, et al.A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma Blood Cancer J, 11 (9) (2021), p. 149

115 J. Bhadury, L.M. Nilsson, S.V. Muralidharan, et al.BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma Proc Natl Acad Sci USA, 111 (26) (2014), pp. E2721-E2730

116 C.E. Ryan, M.S. DavidsBCL-2 inhibitors, present and future Cancer J, 25 (6) (2019), pp. 401-409

117 A.D. Zelenetz, G. Salles, K.D. Mason, et al.Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial Blood, 133 (18) (2019), pp. 1964-1976

118 P. Jain, M. WangMantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management Am J Hematol, 94 (6) (2019), pp. 710-725

119 J.J. Castillo, S.P. TreonManagement of Waldenström macroglobulinemia in 2020 Hematology Am Soc Hematol Educ Program, 2020 (1) (2020), pp. 372-379

120 M. Konopleva, A. LetaiBCL-2 inhibition in AML: an unexpected bonus? Blood, 132 (10) (2018), pp. 1007-1012

121 T.E.C. Cummin, K.L. Cox, T.D. Murray, et al.BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression Blood Adv, 4 (14) (2020), pp. 3316-3328

122 M.H. Bui, X. Lin, D.H. Albert, et al.Preclinical characterization of BET family bromodomain inhibitor ABBV-075 suggests combination therapeutic strategies Cancer Res, 77 (11) (2017), pp. 2976-2989

123 R. Gabizon, N. LondonA fast and clean BTK inhibitor J Med Chem, 63 (10) (2020), pp. 5100-5101

124 S. Pal Singh, F. Dammeijer, R.W. HendriksRole of bruton's tyrosine kinase in B cells and malignancies Mol Cancer, 17 (1) (2018), p. 57

125 M. Boi, E. Gaudio, P. Bonetti, et al.The BET bromodomain inhibitor OTX015 affects pathogenetic pathways in preclinical B-cell tumor models and synergizes with targeted drugs Clin Cancer Res, 21 (7) (2015), pp. 1628-1638

126 E. Derenzini, P. Mondello, T. Erazo, et al.BET inhibition-induced GSK3β feedback enhances lymphoma vulnerability to PI3K inhibitors Cell Rep, 24 (8) (2018), pp. 2155-2166

127 J.R. Vangala, A. Potluri, S.K. RadhakrishnanBET inhibitors synergize with carfilzomib to induce cell death in cancer cells via impairing Nrf1 transcriptional activity and exacerbating the unfolded protein response Biomolecules, 10 (4) (2020), p. 501

128 S.V. Muralidharan, J. Bhadury, L.M. Nilsson, L.C. Green, K.G. McLure, J.A. NilssonBET bromodomain inhibitors synergize with ATR inhibitors to induce DNA damage, apoptosis, senescence-associated secretory pathway and ER stress in Myc-induced lymphoma cells Oncogene, 35 (36) (2016), pp. 4689-4697

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

The Wnt-dependent and Wnt-independent functions of BCL9 in development, tumorigenesis, and immunity: Implications in therapeutic opportunities

Clinical applications of the CRISPR/Cas9 genome-editing system: Delivery options and challenges in precision medicine

Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics

COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery

Regulation mechanism and pathogenic role of lncRNA plasmacytoma variant translocation 1 (PVT1) in human diseases

Related Author

Jianxiang Chen

Fangtian Bu

Haojin Gao

Mengqing Sun

Chao Xu

Heng Dong

Minjie Wu

Marziyeh Mousazadeh

Related Institution

Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University

Laboratory of Cancer Genomics, Division of Cellular and Molecular Research, National Cancer Centre

College of Pharmacy and Department of Hepatology, Institute of Hepatology and Metabolic Diseases, The Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University

National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran

Department of Reproductive Biology, Academic Center for Education, Culture, and Research (ACECR), Qom Branch, Qom 371698

⁰